PMV PHARMACEUTICALS, INC. Investing Cash Flow
PMV PHARMACEUTICALS, INC. (PMVP) reported Investing Cash Flow of $8.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$12.23M, a 211.30% decline year-over-year.
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $20.82M, a 27.48% decline year-over-year.
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $18.44M, a 138.17% increase year-over-year.
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $12.03M, a 29.74% decline year-over-year.
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2025 was $70.17M, a 31.53% increase from fiscal 2024.
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2024 was $53.35M.
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2023 was -$50.55M.
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2022 was -$1.37M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$12.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $8.60M 10-Q · filed 2026-08-14 | $27.04M derived: sum of 3 quarters · filed 2026-08-14 | $39.07M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $20.82M 10-Q · filed 2026-05-12 | $39.27M derived: sum of 2 quarters · filed 2026-05-12 | $51.30M derived: sum of 3 quarters · filed 2026-05-12 | $62.28M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $18.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $30.47M derived: sum of 2 quarters · filed 2026-03-06 | $41.46M derived: sum of 3 quarters · filed 2026-08-14 | $70.17M 10-K · filed 2026-03-06 |
| 2025-09-30 | $12.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $23.01M derived: sum of 2 quarters · filed 2026-08-14 | $51.73M 10-Q · filed 2025-11-12 | $59.47M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $10.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $39.70M 10-Q · filed 2026-08-14 | $47.44M derived: sum of 3 quarters · filed 2026-08-14 | $64.56M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $28.71M 10-Q · filed 2026-05-12 | $36.46M derived: sum of 2 quarters · filed 2026-05-12 | $53.58M derived: sum of 3 quarters · filed 2026-05-12 | $55.90M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $7.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $24.86M derived: sum of 2 quarters · filed 2026-03-06 | $27.19M derived: sum of 3 quarters · filed 2026-03-06 | $53.35M 10-K · filed 2026-03-06 |
| 2024-09-30 | $17.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $19.44M derived: sum of 2 quarters · filed 2025-11-12 | $45.61M 10-Q · filed 2025-11-12 | $43.02M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-06-30 | $2.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $28.49M 10-Q · filed 2025-08-07 | $25.90M derived: sum of 3 quarters · filed 2026-03-06 | -$7.74M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-03-31 | $26.17M 10-Q · filed 2025-05-09 | $23.58M derived: sum of 2 quarters · filed 2026-03-06 | -$10.06M derived: sum of 3 quarters · filed 2026-03-06 | -$74.02M derived: sum of 4 quarters · filed 2026-03-06 |
| 2023-12-31 | -$2.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$36.23M derived: sum of 2 quarters · filed 2026-03-06 | -$100.19M derived: sum of 3 quarters · filed 2026-03-06 | -$50.55M 10-K · filed 2026-03-06 |
| 2023-09-30 | -$33.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$97.60M derived: sum of 2 quarters · filed 2024-11-07 | -$47.96M 10-Q · filed 2024-11-07 | -$24.73M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$63.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$14.32M 10-Q · filed 2024-08-08 | $8.90M derived: sum of 3 quarters · filed 2025-03-03 | $38.42M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $49.65M 10-Q · filed 2024-05-09 | $72.87M derived: sum of 2 quarters · filed 2025-03-03 | $102.38M derived: sum of 3 quarters · filed 2025-03-03 | $87.10M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $23.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $52.74M derived: sum of 2 quarters · filed 2025-03-03 | $37.46M derived: sum of 3 quarters · filed 2025-03-03 | -$1.37M 10-K · filed 2025-03-03 |
| 2022-09-30 | $29.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $14.23M derived: sum of 2 quarters · filed 2023-11-09 | -$24.59M 10-Q · filed 2023-11-09 | -$17.03M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$15.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$54.10M 10-Q · filed 2023-08-09 | -$46.55M derived: sum of 3 quarters · filed 2024-02-29 | -$47.24M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$38.83M 10-Q · filed 2023-05-10 | -$31.27M derived: sum of 2 quarters · filed 2024-02-29 | -$31.96M derived: sum of 3 quarters · filed 2024-02-29 | -$42.51M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $7.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $6.87M derived: sum of 2 quarters · filed 2024-02-29 | -$3.69M derived: sum of 3 quarters · filed 2024-02-29 | -$143.58M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$693.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$11.25M derived: sum of 2 quarters · filed 2022-11-08 | -$151.14M 10-Q · filed 2022-11-08 | -$151.20M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | -$10.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$150.45M 10-Q · filed 2022-08-09 | -$150.51M derived: sum of 3 quarters · filed 2023-03-01 | -$142.47M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$139.90M 10-Q · filed 2022-05-10 | -$139.95M derived: sum of 2 quarters · filed 2023-03-01 | -$131.92M derived: sum of 3 quarters · filed 2023-03-01 | -$105.60M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | -$57.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $7.98M derived: sum of 2 quarters · filed 2023-03-01 | $34.30M derived: sum of 3 quarters · filed 2023-03-01 | $27.91M 10-K · filed 2023-03-01 |
| 2020-09-30 | $8.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $34.35M derived: sum of 2 quarters · filed 2021-11-12 | $27.97M 10-Q · filed 2021-11-12 | $9.41M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $26.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $19.93M 10-Q · filed 2021-08-13 | $1.38M derived: sum of 3 quarters · filed 2022-03-01 | |
| 2020-03-31 | -$6.38M 10-Q · filed 2021-05-14 | -$24.94M derived: sum of 2 quarters · filed 2022-03-01 | ||
| 2019-12-31 | -$18.55M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $3.23M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $21.79M 10-Q · filed 2020-11-13 | |||
| 2018-12-31 | $21.69M 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |